Minocycline, an antibiotic and a neuroprotective: Justifying role in Alzheimer's disease

Asian Journal of Pharmaceutical and Clinical Research

Volumn 3, Issue 3, 2010, Pages 142-145

  Sharma, Vivek Kumar ^a   Goyal, Ashok ^b   Ganti, Subrahmanya Sarma ^c  

^a Govt College of Pharmacy   (India)

^b Onkar College of Pharmacy   (India)

^c ISF COLLEGE OF PHARMACY   (India)

Author keywords

Alzheimer's disease; CNS; Minocycline

Indexed keywords

MINOCYCLINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; TETRACYCLINE DERIVATIVE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; APOPTOSIS; BRAIN ISCHEMIA; DRUG ABSORPTION; DRUG MECHANISM; DRUG PENETRATION; ENCEPHALITIS; ENZYME ACTIVATION; EXCITOTOXICITY; HUMAN; HUNTINGTON CHOREA; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; REVIEW; RISK FACTOR; TRAUMATIC BRAIN INJURY;

EID: 77957602890     PISSN: 09742441     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Selkoe DJ. Soluble oligomers of the amyloid β protein impair synaptic plasticity and behavior. Behavioural Brain Research.2008; 192: 106-113.
2. Yankner BA. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron.1996; 16: 921-932.
3. Dua JS, Prasad DN, Avinash C, Tripathi,Gupta R. Role of traditional medicine in neuropsychopharmacology. Asian Journal of Pharmaceutical and Clinical Research.2009; 2(2):1091-1095.
4. Selkoe D J. Pathophysiological basis of Alzheimer's disease. Nature.1999; 399: 23-31.
5. Abass A, Christopher C and Franz F. Cerebral Ischemia and Alzheimer's Disease: Critical Role of PET and Implications for Therapeutic Intervention. The journal of nuclear medicine.1998; 39(8):231-238.
6. Linda A. Kotilinek, Brian B, Marcus W, Takeshi Kawarabayashi, Linda Y, Bradley T. Hyman, Steven Y and Karen H. Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease. The Journal of Neuroscience.2002;22(15):6331-6335.
7. Quadros A, Ophelia I W, Ghania A G. Role of tau in Alzheimer's dementia and other neurodegenerative diseases. J. Appl. Biomed.2007; 1-12.
8. Dubravka C, Milica S, Slobodan D. Neuropathological hallmarks ofAlzheimer's disease. Archive of Oncology. 2001;9(3):195-197.
9. Ben-yan, Xu Z, Chen Z, Chen F,Tang M. Investigation on apoptosis of neuronal cell sinduced by Amyloid beta-Protein J Zhejiang Univ SCI. 2004; 5(8):989-994.
10. Maurer K, Volk S, Gerbaldo H. Auguste D and Alzheimer's disease. Lancet. 1997; 349:1546-1549.
11. Zilka N, Ferencik M, Hulin I. Neuroinflammation in Alzheimer's disease; protector or promoter. Bratisl Lek Listy.2006; 107(9-10): 374-381.
12. Olivier F, Thomas A, Sandson MD. The Neurobiology and Pharmacotherapy of Alzheimer's disease. J Neuropsychiatry Clin Neurosci.1999; 11(1):132-139.
13. Coleman P, Federoff H, Kurlan R. A focus on the synapse for neuroprotectionin Alzheimer disease and other dementias. Neurology.2004; 63:1155-1162.
14. Gomez-Isla T et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann.Neurol.1997; 41: 17-24.
15. Lucas JG et al. Decreased nuclear b-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3b conditional transgenic mice. The EMBO Journal.2001;20(1,2): 27-39.
16. Guo-Gang XU, Yan-Qiu D, Shi-Jie L, Hong-Lian LI and Jian-Zhi W. Prolonged Alzheimer-like Tau Hyperphosphorylation Induced by Simultaneous Inhibition of Phosphoinositol-3 Kinase and Protein Kinase C in N2a cells. Acta Biochimica et Biophysica Sinica. 2005; 37(5): 349-354.
17. Alonso AC, Grundke-Iqbal I, Iqbal K. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med. 1996; 2: 783-787.
18. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev.2001; 8:741-766.
19. Zhang-Nunes SX, Maat-Schiemann ML, Van Duinen SG, Roos RA, Frosch MP, Greenberg SM. The cerebral beta-amyloid angiopathies: hereditary and sporadic. Brain Pathol.2006; 16:30-39.
20. Butterfield DA, Yatin SM, Varadarajan S & Koppal T. Amyloid beta-peptide-associated free radical oxidative stress, neurotoxicity, and Alzheimer's disease. Methods Enzymol.1999; 309: 746-768.
21. Juurlink BH, Thorburne SK, Hertz L. Peroxide-scavenging deficit underlies oligodendrocytes susceptibility to oxidative stress. Glia.1998; 22: 371-378.
22. Subasinghe S, Unabia S, Barrow CJ, Mok SS, Agulilar MI, Small DH. Cholesterol is necessary both for the toxic effect of Abeta peptides onvascular smooth muscle cells and for Abeta binding to vascular smooth muscle cell membranes. J Neurochem.2003; 84: 471-93.
23. Chopra I and Marilyn R. Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance. Microbiology and moleculer biology reviews. 2001;65(2): 232-260
24. Amin A R et al. A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases. Proc. Natl. Acad. Sci. 1996; 93: 14014-14019.
25. Sande M A & Mandell G L. The Pharmacological Basis of Therapeutics, eds. Goodman, L. S. & Gilman, A. (Macmillan,New York), 1170-1192.
26. Golub L M, Ramamurthy N S & McNamara T F.Reviewing progress in neuropsychophramacology. Crit. Rev. Oral Biol. Med.1991; 2: 297-322.
27. Maragoudakis, M. E., Peristeris, P., Missirls, P., Aletras, A.,Anriopoulou, P. & Haralapoulos, G. (1994) Ann. N. Y. Acad. Sci.732, 280-293.
28. Scarabelli TM, Kight R, Stephanou A. Clinical implications of apoptosis in ischemic myocardium. Curr Probl Cardiol. 2006; 31: 181-264.
29. Blum D, Chtarto A, Tenenbaum L, Brotchi J, Levivier M. Clinical potential of Minocycline for neurodegenerative disorders. Neurobiol Disease. 2004; 17: 359-366.
30. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci. 2001; 2: 502-11.
31. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci.1999; 96: 13496-500.
32. Sanchez Mejia RO, Ona VO, Li M, Friendlander RM. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery 2001; 48: 1393-1399.
33. Zhu S et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 2002; 417: 74-78.
34. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci. 2002; 22: 1763-1771.
35. Heo K, Cho YJ, Cho KJ, Kim HW, Kim HJ, Shin HY et al. Minocycline inhibits caspase-dependent and-independent cell death pathways and is neuroprotective against hippocampal damage after treatment with kainic acid in mice. Neurosci Lett. 2006; 398: 195-200.
36. Wang J, Wei Q, Wang CY, Hill WD, Hess DC, Dong Z. Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria J Biol Chem. 2004; 279: 19948-54.
37. Popovic N, Schubart A, Goetz BD, Zhang SC, Linington C, Duncan ID. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol. 2002;51: 215-223.
38. Cho KO, La HO, Cho YJ, Sung KW, Kim SW. Minocycline attenuates white matter damage in a rat model of chronic cerebral hypoperfusion. J Neurosci Res. 2006; 83: 285-291.
39. Kumar A, Seghal N, Padi S V, Naidu P S. Differential effects of cyclooxygenase inhibitors on intracerebroventricular colchicineinduced dysfunction and oxidative stress in rats. Europ. J. Pharmacol.2006; 551: 58-66.
40. Sarkar P K. Degeneration and death of neurons in adult neurodegenerative diseases. Curr. Sci.2005; 89:132-135.
41. Kihara T and Shimohana S.Alzheimer's disease and acetylcholine receptors. Acta. Neurobiol. Exp.2004; 64: 99-105.
42. Tikka TM, Koistinaho JE. Minocycline provides neuroprotection against N-methyl-d-aspartate neurotoxicity by inhibiting microglia. J. Immunol.2001; 166: 7527-7533.
43. Zilka N, Ferencik M, Hulin I. Neuroinflamation in Alzheimer's disease; protector or promoter. Bratisl Lek Listy.2006; 107(9-10): 374-381.
44. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole G. M. Inflammation and Alzheimer's disease. Neurobiol. Aging.2000; 21: 383-421.
45. Tuppoa E and Ariasb H R. The role of inflammation in Alzheimer's disease. Intern. J. Biochem. Cell Biol.2005; 37: 289-305.
46. Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP. The role of glial reaction and inflammation in Parkinson's disease. AnnNY Acad Sci.2003; 991:214-228.
47. Streit WJ. Microglia and Alzheimer's disease pathogenesis. J Neurosci Res.2004; 77:1-8.
48. Seabrook TJ, Jiang L, Maier M, Lemere C. Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia.2006; 53: 776-782.
49. Choi Y, Hye-Sun Kim, Ki YS, Eun-Mee K, Minji Kim, Hyun-Soo Kim et al. Minocycline Attenuates Neuronal Cell Death and Improves Cognitive Impairment in Alzheimer's Disease Models. Neuropsychopharmacology. 2007;32: 2393-2404.
50. Teng YD, Choi H, Onario RC et al. Minocycline inhibits contusiontriggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury.Proc Natl Acad Sci. 2004; 101: 3071-76.
51. Arvin KL, Han BH, Du Y, Lin SZ, Paul SM, Holtzman DM. Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol. 2002; 52: 54-61.
52. Wang J, Wei Q, Wang CY, Hill WD, Hess DC, Dong Z. Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria J Biol Chem. 2004; 279: 19948-54.
53. Brasnjevic I, Patrick RH, Harry WM. Accumulation of nuclear DNA damage or neuron loss: Molecular basis for a new approach to understanding selective neuronal vulnerability in neurodegenerative diseases. DNA Repair.2008; 7: 1087-1097.
54. Love S, Barber L and Wilcock GK. Increased poly (ADPribosyl) ation of nuclear proteins in Alzheimer's disease. Brain.1999; 122: 247-253.
55. Weinfeld M, Chaudhry MA, D'Amours D, Pelletier JD, Poirier GG, Povirk LF, et al. Interaction of DNA-dependent protein kinase andpoly(ADP-ribose) polymerase with radiation-induced DNA strand breaks. Radiat Res 1997; 148: 22-28.
56. Hong SJ, Dawson TM, Valina L.Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. TRENDS in Pharmacological Sciences 2004; 25:1221-31.
57. Mark PM, Magnus T. Ageing and neuronal vulnerability Nature reviews; 2006: 7: 279-281.
58. Zhang J, Dawson VL, Dawson TM, Snyder SH. Nitric oxide activationof poly (ADP-ribose) synthetase in neurotoxicity. Science 1994; 263:687-689.
59. Alano CC, Tiina M, Kauppinen A, Viader V and Raymond AS.Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations.PNAS.2006;103(25)9685-9690.
60. Domercq M, Matute C. Neuroprotection by tetracyclines. Trends Pharmacol Sci.2004, 25:609-612.
61. Song Y, Wei EQ, Zhang WP, Zhang WP, Zhang L, Liu JR, Chen Z. Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation. Neuroreport. 2004; 15:2181-2184.
62. Klegeris A, McGeer PL. Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neurobiol Aging. 2003; 23:787-794.
63. Matsukawa N, Takao Y, Koichi H, Lin X, Mina M et al.Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke.BMC Neuroscience.2009;10:126-131.